ClinicalTrials.gg
RecruitingNCT07655518Updated Jul 10, 2026

A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

A Phase 1 interventional study of BMS-986521 in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
  • BMS-986521
  • Positron Emission Tomography
  • PET tracer
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy male and female (as assigned at birth) who are individuals not of (INOCBP) without deviation from normal in medical history, PE, 12-lead , and clinical laboratory assessments.
  • Participants must have a of 18 to 30 kg/m\^2, inclusive, and total body weight ≥ 50 kg.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have presence or history of any abnormality, condition, or disease-CNS, cardiovascular, renal, hepatic, hematologic, GI, endocrine, pulmonary, psychiatric, neurologic (eg, seizure disorder), or immunologic.
  • Participants must not have history of rhabdomyolysis.
  • Participants must not have current or recent (within 3 months of study intervention administration) clinically significant GI disease.
  • Other protocol defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    BMS-986521: Cohort 1

    Drug: BMS-986521

  • Experimental
    BMS-986521: Cohort 2

    Drug: BMS-986521

  • Experimental
    BMS-986521: Cohort 3

    Drug: BMS-986521

Interventions

  • DrugBMS-986521

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Percentage occupancy of M4 receptor in the brain

    Based on PET scans

    Time frame: Up to approximately 28 hours after last dose

Secondary outcomes

  1. Number of participants with treatment-emergent AEs (TEAEs)

    Time frame: Up to Day 38

  2. Number of participants with treatment-emergent serious AEs (SAEs)

    Time frame: Up to Day 38

  3. Number of participants with treatment-emergent suicidal ideation and behavior

    Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to Day 11

  4. Maximum Concentration (Cmax) of BMS-986521 in Plasma

    Time frame: Up to Day 11

  5. Area Under the Concentration-Time Curve from Time Zero to 24 Hours (AUC(0-24)) of BMS-986521 in Plasma

    Time frame: Up to Day 11

  6. Time to Cmax (Tmax) of BMS-986521 in Plasma

    Time frame: Up to Day 11

  7. Effective half-life (T-HALFeff) of BMS-986521 in Plasma

    Time frame: Up to Day 11

  8. Apparent Clearance of BMS-986521 from Plasma after Dosing (CLT/F)

    Time frame: Up to Day 11

  9. Apparent Volume of Distribution in Plasma after Dosing (Vz/F) of BMS-986521

    Time frame: Up to Day 11

  10. Maximal effect (Emax)

    Plasma concentrations of BMS-986521 versus M4 receptor occupancy

    Time frame: Up to approximately 28 hours after last dose

  11. Half maximal effective concentration (EC50)

    Plasma concentrations of BMS-986521 versus M4 receptor occupancy

    Time frame: Up to approximately 28 hours after last dose

07

Study locations

1 of 1 sites recruiting
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
    Recruiting
    • Koen Van Laere, Site 0001 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 18, 2026
StartActual
Jun 25, 2026
Primary completionEst.
Dec 27, 2026
CompletionEst.
Dec 27, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07655518
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Jun 25, 2026
Primary completion
Dec 27, 2026 (estimated)
Completion
Dec 27, 2026 (estimated)
Last update
Jul 10, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion